Management of secondary-progressive multiple sclerosis (Q35843538)

10 August 2017

1 reference

title

Management of secondary-progressive multiple sclerosis (English)

1 reference

secondary progressive multiple sclerosis

10 August 2017

main subject

0 references

author name string

Gavin Giovannoni

series ordinal

1

1 reference

10 August 2017

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

18

1 reference

10 August 2017

issue

10

1 reference

10 August 2017

page(s)

653-669

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200418100-00003

10 August 2017

exact match

0 references

cites work

The treatment of neuropathic pain: antidepressants and opioids

1 reference

12 December 2020

Recent developments in the management of detrusor overactivity

1 reference

12 December 2020

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

12 December 2020

Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis

1 reference

12 December 2020

Insulin-like growth factor-I receptors in normal appearing white matter and chronic plaques in multiple sclerosis.

1 reference

12 December 2020

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

1 reference

12 December 2020

Insulin-like growth factor I protects oligodendrocytes from tumor necrosis factor-alpha-induced injury

1 reference

12 December 2020

Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group

1 reference

12 December 2020

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b

1 reference

12 December 2020

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

12 December 2020

The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group

1 reference

12 December 2020

Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone

1 reference

12 December 2020

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

12 December 2020

Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group

1 reference

12 December 2020

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

1 reference

12 December 2020

The current status of studies of aminopyridines in patients with multiple sclerosis

1 reference

12 December 2020

Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group

1 reference

12 December 2020

Imaging axonal damage in multiple sclerosis by means of MR spectroscopy

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

1 reference

12 December 2020

Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

1 reference

12 December 2020

A controlled trial of isoniazid therapy for action tremor in multiple sclerosis

1 reference

12 December 2020

An open-trial evaluation of mitoxantrone in the treatment of progressive MS.

1 reference

12 December 2020

Biological markers of the inflammatory phase of multiple sclerosis

1 reference

12 December 2020

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

1 reference

12 December 2020

Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis

1 reference

12 December 2020

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

1 reference

12 December 2020

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community?

1 reference

12 December 2020

Suppression of demyelination by mitoxantrone

1 reference

12 December 2020

The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis.

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

12 December 2020

Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS.

1 reference

12 December 2020

A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor.

1 reference

12 December 2020

Presenting an odd autoantigen

1 reference

12 December 2020

The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome.

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Building an evidence base for multiple sclerosis management: support for physiotherapy

1 reference

12 December 2020

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis

1 reference

12 December 2020

Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.

1 reference

12 December 2020

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

12 December 2020

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

1 reference

12 December 2020

Corticosteroid-induced hypersensitivity reactions

1 reference

12 December 2020

The 'Queen Square bladder stimulator': a device for assisting emptying of the neurogenic bladder

1 reference

12 December 2020

Relationship between disease activity and dose-response relationships with beta interferon therapies in the treatment of multiple sclerosis

1 reference

12 December 2020

Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

1 reference

12 December 2020

Corticosteroids and multiple sclerosis

1 reference

12 December 2020

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

12 December 2020

Relapses and progression of disability in multiple sclerosis

1 reference

12 December 2020

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

12 December 2020

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

12 December 2020

Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS

1 reference

12 December 2020

Neuregulin and erbB receptor expression in normal and diseased human white matter

1 reference

12 December 2020

Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy

1 reference

12 December 2020

Citalopram for post-stroke pathological crying

1 reference

12 December 2020

Evidence for multiple sclerosis as an infectious disease.

1 reference

12 December 2020

Overview of azathioprine treatment in multiple sclerosis

1 reference

12 December 2020

Complex disease and the new clinical sciences

1 reference

12 December 2020

Adverse psychiatric effects of systemic glucocorticoid therapy

1 reference

12 December 2020

Diagnostic criteria for primary progressive multiple sclerosis: a position paper

1 reference

12 December 2020

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

12 December 2020

Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose

1 reference

12 December 2020

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1 reference

12 December 2020

Rapid response of emotional incontinence to selective serotonin reuptake inhibitors.

1 reference

12 December 2020

Anticonvulsants in central pain

1 reference

12 December 2020

A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects

1 reference

12 December 2020

Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial.

1 reference

12 December 2020

Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity.

1 reference

12 December 2020

Autoimmunity can benefit self-maintenance

1 reference

12 December 2020

Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study

1 reference

12 December 2020

Maneuvering in the complex path from genotype to phenotype

1 reference

12 December 2020

Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone

1 reference

12 December 2020

New treatments and azathioprine in multiple sclerosis

1 reference

12 December 2020

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

12 December 2020

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Axonal loss in normal-appearing white matter in a patient with acute MS.

1 reference

12 December 2020

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

12 December 2020

ESIMS--an ongoing clinical trial in secondary progressive multiple sclerosis.

1 reference

12 December 2020

Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group

1 reference

12 December 2020

Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo

1 reference

12 December 2020

Multiple sclerosis: the disease and its manifestations

1 reference

12 December 2020

Treatment of spasticity with botulinum toxin: a double-blind study

1 reference

12 December 2020

Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials

1 reference

12 December 2020

Epitope spreading in immune-mediated diseases: implications for immunotherapy

1 reference

12 December 2020

Targeting the chemokine system for multiple sclerosis treatment

1 reference

12 December 2020

Epidemiologic evidence for multiple sclerosis as an infection

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Multiple paradigm shifts in multiple sclerosis

1 reference

12 December 2020

A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group

1 reference

12 December 2020

Epilepsy and multiple sclerosis

1 reference

12 December 2020

Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis

1 reference

12 December 2020

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1 reference

12 December 2020

The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure

1 reference

12 December 2020

Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup

1 reference

12 December 2020

Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role?

1 reference

12 December 2020

Acquired channelopathies in nerve injury and MS.

1 reference

12 December 2020

Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination

1 reference

12 December 2020

The role of microglia macrophages in the processes of inflammatory demyelination and remyelination

1 reference

12 December 2020

Treatments for fatigue in multiple sclerosis: a rapid and systematic review

1 reference

12 December 2020

A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility.

1 reference

12 December 2020

A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations

1 reference

12 December 2020

Discrepancies between meta-analyses and subsequent large randomized, controlled trials

1 reference

12 December 2020

10.2165/00023210-200418100-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1047664188

0 references

Fatcat ID

release_a2xkaj2wkzazzclixcmlsezuf4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/a2xkaj2wkzazzclixcmlsezuf4

24 November 2022

mapped directly with Wikidata item

1 reference